Serologic markers in the diagnosis and management of pancreatic carcinoma

摘要: The low prevalence of pancreatic cancer remains an inherent obstacle to the development effective screening tools in asymptomatic population. However, these difficulties do not warrant nihilism. Development serologic markers still offers potential for improvement our diagnostic capabilities. accurate identification patients with and exclusion disease those benign disorders remain important goals. While alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), carcinoembryonic antigen (CEA), ribonuclease (RNase) can be largely dismissed as useful cancer, leukocyte adherence inhibition (LAI), oncofetal (POA), galactosyltransferase isoenzyme II (GT-II) continue show promise. Each currently requires further technical improvements permit more widescale evaluation. refinement monoclonal antibody defined such gastrointestinal antigens (GICA) may provide even future. help identify early disease, impetus develop therapeutic strategies. It seen whether modalities translated into clinical outcome.